Skip to content
Home / News |

Emergent Biosolutions Stock Tanks 42% on ‘No-Deal’ Covid Vaccine

The stock price of Emergent Biosolutions (NYSE: EBS)  plummeted around 42% in the middle of Friday’s trading. The vaccine manufacturer has reached a mutual agreement with the government to cancel a sizeable vaccine contract. 

Canceling a $628M contract can’t be easy – yet the problems over at Emergent simply aren’t worth the risk, leading the government to cancel the anticipated contract and leaving Emergent $180M out of pocket. Sure enough, that was enough to terrify Emergent’s investors, sparking the mid-market sell-off of 42%. 

The unfortunate downfall began in March, when the company was blamed for ruining millions of Johnson & Johnson Covid doses after apparent contamination, supporting degrading claims of an unsanitary manufacturing plant. Following the canceled contract, J & J will take over control of vaccine production – leaving investors seeming rather lost. 

WELCOME BONUS - Free Share Bundle When You Invest £50! Open a UK Investment Account: Shares, ISAs, Managed Portfolio Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply. IG
5.0
View Offers
Empfohlener Broker Multi Asset Platform
Social-Trading-Pionier mit Aktien, ETFs, Krypto und CFDs, Copy Trading inklusive. eToro
5.0
Weitere Informationen 50% of retail investor accounts lose money when trading CFDs with this provider.

Due to contract differences, Emergent will continue to work with J & J at the company’s Baltimore plant – where Emergent has contributed to “over 100 million dose equivalents of Covid vaccine”. The news hits just as Pfizer receive positive results for their new Covid-19 antiviral drug.

Emergent CEO Robert Kramer stated: 

“The work we accomplished under the program and related task order contracts with the U.S. government served a critically important purpose…one that our entire organization is immensely proud of.”

Emergent has suffered a critical hit to its shareholders. Losing a contract like this can cause enormous damage to the companies wider strategy, as well as closing the door on possible investment. EBS stock has suffered a daily loss of 41.6% at the time of writing, with price sitting at $30.80.

Should You Invest in Emergent Biosolutions Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

Nigel F
Author